Pharmacodynamics: Targeted Action on the Immune System
Omalizumab (known by the brand name Xolair) is a recombinant humanized monoclonal antibody. It is a classic example of targeted therapy aimed at a specific immunological link in the pathogenesis of allergic reactions. The primary and sole target of this drug is immunoglobulin E (IgE).
The mechanism of action is realized in two stages, encompassing primary and secondary pharmacological effects.
The primary mechanism of action is based on the selective binding of the drug molecule to free human IgE circulating in blood plasma. By forming a stable complex, the drug rapidly reduces the pool of free IgE.
The consequences of this binding include:
- A sharp decrease in the number of IgE molecules capable of attaching to high-affinity receptors (known as $Fc\epsilon RI$) on the surface membranes of mast cells.
- Interruption of mast cell sensitization and subsequent activation.
- A predictable reduction in the massive release of allergic mediators (primarily histamine and other biologically active substances).
The secondary (long-term) effect manifests with regular, long-term administration of the antibody. It involves down-regulation: the body adapts to low levels of free IgE, leading to a decrease in the density of $Fc\epsilon RI$ receptors themselves on mast cell membranes. Additionally, as a long-term consequence, the de novo synthesis of new IgE molecules by B lymphocytes is suppressed.
Specificity, Safety, and Clinical Effects
A key pharmacological feature of omalizumab, which determines its safety profile, is its strict selectivity. The drug binds exclusively to free IgE in blood plasma and does not interact with immunoglobulin E already fixed to the surface of mast cells.
As a consequence of this high specificity, the drug molecules do not cause cross-linking (agglutination) of mast cells. This prevents their degranulation in response to drug administration. Thus, the risk of provoking an acute allergic reaction by the drug itself is eliminated.
In clinical practice, anti-IgE therapy provides the following significant effects:
- A reliable reduction in the frequency and severity of asthma exacerbations.
- Restoration of corticosteroid sensitivity. This is a critically important aspect of treatment that helps overcome resistance to inhaled corticosteroids and regain control over severe disease.
Indications, Dosing Regimen, and Adverse Effects
In modern pharmacotherapy, omalizumab is considered a reserve drug. Its main clinical indication is bronchial asthma that is refractory (resistant) to conventional controller therapy.
Dosing Regimen and Routes of Administration:
- Route: Administered primarily subcutaneously, although intravenous use has also been described in clinical practice.
- Dosage: A single dose ranges from 150 to 375 mg.
- Frequency: Injections are administered every 2 to 4 weeks to maintain stable suppression of free IgE.
Adverse Effects: Despite its targeted mechanism of action, monoclonal antibody therapy may be accompanied by several adverse reactions, divided into three groups:
- Infectious complications: Due to immunomodulatory effects, patients may experience upper respiratory tract infections (predominantly viral).
- Local reactions: Transient pain, skin redness, and local pruritus may occur directly at the injection site.
- Systemic reactions: Systemic manifestations include headache and the risk of allergic reactions to the recombinant protein.